Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/2008

01-03-2008 | Epidemiology

Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers

Authors: T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wiśniowski, M. Siolek, S. A. Narod, J. Lubinski, the Polish Hereditary Breast Cancer Consortium

Published in: Breast Cancer Research and Treatment | Issue 2/2008

Login to get access

Abstract

Purpose

There have been no studies to date which look at the relative effectiveness of different regimens of chemotherapy in women who have breast cancer and who carry a BRCA1 germ-line mutation. We wished to compare rates of response to neo-adjuvant chemotherapy in BRCA1 mutation carriers and non-carrier controls.

Experimental design

From a registry of 3,479 patients, we identified 44 Polish women who carried a BRCA1 founder mutation and who had been treated with neo-adjuvant chemotherapy for breast cancer, and 41 age- and hospital-matched controls.

Results

35 of the 44 BRCA1 mutation carriers (80%) experienced a partial or complete response to neo-adjuvant chemotherapy, compared to 39 of the 41 (95%) non-carriers (P = 0.05). In the hereditary subgroup, response rates differed depending on whether or not a taxane (docetaxel) was given. Six of the 15 BRCA1 carrier women given docetaxel with doxorubicin responded (complete or partial), compared to 29 of 29 given other (DNA-damaging) therapies (P = 0.001). Among the non-carriers, the rates of response to the two categories of chemotherapy were similar.

Conclusions

Breast cancers among BRCA1 carriers frequently do not exhibit sensitivity to docetaxel in the neo-adjuvant setting. It is likely that normal BRCA1 is required for clinical response to mitotic spindle poisons.
Literature
1.
Marcus JN, Watson P, Page DL et al (1997) BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 44:275–277PubMedCrossRef
2.
Lakhani SR, Jacquemier J, Sloane JP et al (1998) Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 90:1138–1145PubMedCrossRef
3.
Foulkes WD, Brunet JS, Stefansson IM et al (2004) The prognostic implication of the basal-like (cyclin E high/p27 low/p53+/glomeruloid-microvascular-proliferation+) phenotype of BRCA1-related breast cancer. Cancer Res 64:830–835PubMedCrossRef
4.
Johannsson OT, Idvall I, Anderson C et al (1997) Tumour biological features of BRCA1-induced breast and ovarian cancer. Eur J Cancer 33:362–371PubMedCrossRef
5.
Moynahan ME, Cui TY, Jasin M (2001) Homology-directed DNA repair, mitomycin-c resistance, and chromosome stability is restored with correction of a BRCA1 mutation. Cancer Res 61:4842–4850PubMed
6.
Bhattacharyya A, Ear US, Koller BH, Weichselbaum RR, Bishop DK (2000) The breast cancer susceptibility gene BRCA1 is required for subnuclear assembly of Rad51 and survival following treatment with the DNA cross-linking agent cisplatin. J Biol Chem 275:23899–23903PubMedCrossRef
7.
Fedier A, Steiner RA, Schwartz VA et al (2003) The effect of loss of Brca1 on the sensitivity of anticancer agents in p53-deficient cells. Int J Oncol 22:1169–1173PubMed
8.
Chabalier C, Lamare C, Racca C et al (2003) BRCA1 down-regulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cycle 5:1001–1007
9.
Fisher B, Bryant J, Wolmark N et al (1998) Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 16:2672–2685PubMed
10.
Lubinski J, Gorski B, Huzarski T et al (2006) BRCA1-positive breast cancers in young women from Poland. Breast Cancer Res Treat 99:71–76PubMedCrossRef
11.
Górski B, Byrski T, Huzarski T et al (2000) Founder mutations in BRCA1 gene in Polish families with breast-ovarian cancer. Am J Hum Genet 66:1963–1968PubMedCrossRef
12.
Górski B, Jakubowska A, Huzarski T et al (2004) A high proportion of founder BRCA1 mutations in Polish breast cancer families. Int J Cancer 110:683–686PubMedCrossRef
13.
Kennedy RD, Quinn JE, Mullan PB et al (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659–1668PubMedCrossRef
14.
Zhoue C, Smith JL, Lui J (2003) Role of BRCA1 in cellular resistance to paclitaxel and ionizing radiation in an ovarian cancer cell line carrying a defective BRCA1. Oncogene 22:2396–2404CrossRef
15.
Lafarge S, Sulvain V, Ferrara M, Bignon YJ (2001) Inhibition of BRCA1 leads to increased chemoresistance to micotubule-interfering agents, an effect that involves the JNK pathway. Oncogene 20:6597–6606PubMedCrossRef
16.
Quinn JE, Kennedy RD, Mullan PB et al (2003) BRCA1 functions as a diferential modulator of chemotherapy-induced apoptosis. Cancer Res 63:6221–6228PubMed
17.
Tassone P, Tagliaferri P, Perricelli A et al (2003) BRCA1 expression modulates chemosensitivity of BRCA1-defective HCC1937 human breast cancer cells. Br J Cancer 88:1285–1291PubMedCrossRef
18.
Chappuis PO, Goffin J, Wong N et al (2002) A significant response to neoadjuant chemotherapy in BRCA1/2 related breast cancer. J Med Genet 39:608–610PubMedCrossRef
19.
Delaloge S, Kloos I et al (2002) BRCA1-linked breast cancer is highly more chemosensitive than its BRCA2-linked or sporadic counterparts. Program and abstracts of the 27th Congress of the European Society for Medical Oncology 2002
20.
Rouzier R, Perou CM, Symmans WF et al (2005) Breast cancer molecular subtypes respond differently to pre-operative chemotherapy. Clin Cancer Res 11:5678–5685PubMedCrossRef
21.
Foulkes WD, Stefansson IM, Chappuis PO et al (2003) Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 95:1482–1485PubMed
22.
Kennedy RD, Quinn JR, Mullan PB, Johnston PG, Harkin DP (2004) The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst 96:1659–1668PubMedCrossRef
23.
Turner N, Tutt A, Ashworth A (2005) Targeting the DNA repair defect of BRCA tumours. Curr Opin Pharmacol 5:338–393CrossRef
24.
Garber JE, Richardson A, Harris LN et al (2006) Neo-adjuvant cisplatin (CDPP) in “triple-negative” breast cancer. Abstract of the San Antonio Breast Cancer Symposium, San Antonio
Metadata
Title
Response to neo-adjuvant chemotherapy in women with BRCA1-positive breast cancers
Authors
T. Byrski
J. Gronwald
T. Huzarski
E. Grzybowska
M. Budryk
M. Stawicka
T. Mierzwa
M. Szwiec
R. Wiśniowski
M. Siolek
S. A. Narod
J. Lubinski
the Polish Hereditary Breast Cancer Consortium
Publication date
01-03-2008
Publisher
Springer US
Published in
Breast Cancer Research and Treatment / Issue 2/2008
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1007/s10549-007-9600-1

Other articles of this Issue 2/2008

Breast Cancer Research and Treatment 2/2008 Go to the issue

Preclinical Study

Role of manganese superoxide dismutase on growth and invasive properties of human estrogen-independent breast cancer cells

Preclinical Study

Predicting features of breast cancer with gene expression patterns

Clinical Trial

Relation of demographic factors, menstrual history, reproduction and medication use to sex hormone levels in postmenopausal women

Clinical Trial

Phase III randomized multicenter study on the effects of adjuvant CMF in patients with node-negative, rapidly proliferating breast cancer: twelve-year results and retrospective subgroup analysis

Clinical Study

Effects of a combined aerobic and resistance exercise program in breast cancer survivors: a randomized controlled trial

Epidemiology

Epidemiology and economic burden of brain metastases among patients with primary breast cancer: results from a US claims data analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits